FDA
-
-
-
-
-
-
-
Organon presents new VTAMA cream data showing early atopic dermatitis improvement
-
-
-
-
-
-
-
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
-
-
-
-
-
-
-
European Commission approves Henlius and Organon denosumab biosimilars
-
-
-
-
-
-
-
Organon (OGN) and Samsung Bioepis Granted FDA Interchangeability Designation
-
-
-
-
-
-
-
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Old
-
-
-
-
-
-
-
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
-
-
-
-
-
-
-
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
-
322,096 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

